Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc region

J Immunol Methods. 2019 Jan:464:87-94. doi: 10.1016/j.jim.2018.11.002. Epub 2018 Nov 2.

Abstract

The development of biotherapeutics requires continuous improvement in analytical methodologies for the assessment of their quality attributes. A subset of biotherapeutics is designed to interact with specific antigens that are exposed on the membranes of target cells or circulating in a soluble form, and effector functions are achieved via recognition of their Fc region by effector cells that induce mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC). Thus, ADCC induction is a critical quality attribute (CQA) that must be evaluated to ensure biotherapeutic efficacy. Induction of ADCC can be evaluated by employing effector cells from different sources, such as peripheral blood mononuclear cells (PBMC) and genetically modified cell lines (e.g., transfected NKs or Jurkat cells), and different approaches can be used for detection and results interpretation depending on the type of effector cells used. In this regard, validation of the assays is relevant to ensure the reliability of the results according to the intended purpose. Herein, we show the standardization and validation of ADCC assays to test the potency of three biotherapeutic proteins using primary NK cells obtained from fresh blood as effector cells and detecting cell death by flow cytometry. The advantage of using primary NKs instead of modified cells is that the response is closer to that occurring in vivo since cytotoxicity is evaluated in a direct manner. Our results indicate that in all cases, the assays exhibited a characteristic sigmoidal dose/response curve complying with accurate, precise and specific parameters. Thereby, the validated ADCC assay is an appropriate alternative to evaluate the biological activities of these type of biotherapeutics.

Keywords: ADCC; Biotherapeutic products; Primary natural killer cells; Validation assay.

Publication types

  • Validation Study

MeSH terms

  • Adalimumab / pharmacology*
  • Animals
  • Antibody-Dependent Cell Cytotoxicity / drug effects*
  • Antineoplastic Agents, Immunological / pharmacology*
  • Burkitt Lymphoma / drug therapy*
  • Burkitt Lymphoma / immunology
  • Burkitt Lymphoma / pathology
  • CHO Cells
  • Cell Death / drug effects
  • Cell Line, Tumor
  • Cell Separation / methods*
  • Cricetulus
  • Dose-Response Relationship, Drug
  • Etanercept / pharmacology*
  • Flow Cytometry*
  • Humans
  • Killer Cells, Natural / drug effects*
  • Killer Cells, Natural / immunology
  • Primary Cell Culture
  • Reproducibility of Results
  • Rituximab / pharmacology*

Substances

  • Antineoplastic Agents, Immunological
  • Rituximab
  • Adalimumab
  • Etanercept